Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters
Somayeh Nazari, Fatemeh Mosaffa, Alireza Poustforoosh, Motahareh Mortazavi, Luciano Saso, Omidreza Firuzi, Fatemeh Moosavi
Topics & Concepts
PharmacologyAbcg2Tyrosine-kinase inhibitorMultiple drug resistanceCancer cellMTT assayChemistryLapatinibMitoxantroneCancer researchCancerTransporterATP-binding cassette transporterBiologyMedicineCell growthBiochemistryInternal medicineBreast cancerChemotherapyTrastuzumabGeneAntibioticsDrug Transport and Resistance MechanismsLiver physiology and pathologySynthesis and Biological Activity